J Graham Thomas1, Hollie A Raynor2, Dale S Bond1, Anna K Luke1, Chelsi C Cardoso2, Gary D Foster3, Rena R Wing1. 1. Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, The Miriam Hospital Weight Control and Diabetes Research Center, Providence, Rhode Island, USA. 2. Department of Nutrition, University of Tennessee, Knoxville, Tennessee, USA. 3. Weight Watchers International, Inc., New York City, New York, USA.
Abstract
OBJECTIVE: To evaluate a commercial online weight loss program and activity tracker, which are popular but have unknown efficacy. METHODS:Two hundred seventy-nine participants with BMI 27 to 40 kg/m2 were randomized to 12 months of the Weight Watchers Online program alone (WWO) or with the ActiveLink® activity tracking device (WWO+AL) or an online newsletter (Control). RESULTS:Weight losses at 3 months were significantly greater in WWO (2.7 kg [95% confidence interval (CI), 2.0-3.5 kg] than Control (1.3 kg [95% CI, 0.5-2.0 kg]; P = 0.01); neither differed from WWO+AL (2.0 kg [95% CI, 1.3-2.7 kg]; Ps > 0.56). Significantly more WWO participants (24.5%) achieved ≥ 5% weight loss at 3 months than Control (9.4%) (P = 0.01); neither differed from WWO+AL (17.6%) (Ps = 0.13-0.28). At 12 months, there were no significant differences between groups in weight loss (Ps > 0.52). WWO (25.5%) continued to have a higher proportion of participants achieving ≥ 5% weight loss than Control (12.9%) (P = 0.04); neither differed from WWO+AL (14.3%) (Ps > 0.10). There were no significant between-group differences in change in physical activity (Ps > 0.17). CONCLUSIONS: WWO produced significantly more weight loss at 3 months relative to Control, but not at 12 months. Significantly more WWO than Control participants lost ≥ 5% at both 3 and 12 months. Participants receiving anactivity tracking device did not achieve greater weight loss or physical activity increases than those in a Control condition.
RCT Entities:
OBJECTIVE: To evaluate a commercial online weight loss program and activity tracker, which are popular but have unknown efficacy. METHODS: Two hundred seventy-nine participants with BMI 27 to 40 kg/m2 were randomized to 12 months of the Weight Watchers Online program alone (WWO) or with the ActiveLink® activity tracking device (WWO+AL) or an online newsletter (Control). RESULTS: Weight losses at 3 months were significantly greater in WWO (2.7 kg [95% confidence interval (CI), 2.0-3.5 kg] than Control (1.3 kg [95% CI, 0.5-2.0 kg]; P = 0.01); neither differed from WWO+AL (2.0 kg [95% CI, 1.3-2.7 kg]; Ps > 0.56). Significantly more WWO participants (24.5%) achieved ≥ 5% weight loss at 3 months than Control (9.4%) (P = 0.01); neither differed from WWO+AL (17.6%) (Ps = 0.13-0.28). At 12 months, there were no significant differences between groups in weight loss (Ps > 0.52). WWO (25.5%) continued to have a higher proportion of participants achieving ≥ 5% weight loss than Control (12.9%) (P = 0.04); neither differed from WWO+AL (14.3%) (Ps > 0.10). There were no significant between-group differences in change in physical activity (Ps > 0.17). CONCLUSIONS: WWO produced significantly more weight loss at 3 months relative to Control, but not at 12 months. Significantly more WWO than Control participants lost ≥ 5% at both 3 and 12 months. Participants receiving an activity tracking device did not achieve greater weight loss or physical activity increases than those in a Control condition.
Authors: Jeanne M Ferrante; Katie A Devine; Alicja Bator; Ashley Rodgers; Pamela A Ohman-Strickland; Elisa V Bandera; Kevin O Hwang Journal: Transl Behav Med Date: 2020-10-08 Impact factor: 3.046
Authors: Sagun Agrawal; Alexis C Wojtanowski; Laura Tringali; Gary D Foster; Eric A Finkelstein Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Margaret Raber; Yue Liao; Anne Rara; Susan M Schembre; Kate J Krause; Larkin Strong; Carrie Daniel-MacDougall; Karen Basen-Engquist Journal: Public Health Nutr Date: 2021-08-20 Impact factor: 4.022
Authors: D M Manodhi K Saranapala; John Baranoff; R Louise Rushworth; Ian Westley; Kathryn Collins; Anne L J Burke; Andrea Parker; Julio Licinio; Peter M Clifton; David J Torpy Journal: Compr Psychoneuroendocrinol Date: 2022-02-09